Display options
Cite
Castro-Macías JI, Pérez-Reyes SP, García-Cazarez R, et al. Tolerabilidad y efectos adversos del propofol en la prueba de Wada. [Tolerability and adverse effects of propofol in the Wada test]. Rev Neurol. 2021;72(5):151-156doi: 10.33588/rn.7205.2020292.
Castro-Macías, J. I., Pérez-Reyes, S. P., García-Cazarez, R., Pérez-Careta, M. C., Díaz-Campos, M. O., Salazar-Hörner, D. L., Preciado-Gutiérrez, O. U., & Ruíz-Velázquez, F. (2021). Tolerabilidad y efectos adversos del propofol en la prueba de Wada. [Tolerability and adverse effects of propofol in the Wada test]. Revista de neurologia, 72(5), 151-156. https://doi.org/10.33588/rn.7205.2020292
Castro-Macías, J I, et al. "Tolerabilidad y efectos adversos del propofol en la prueba de Wada." [Tolerability and adverse effects of propofol in the Wada test]. Revista de neurologia vol. 72,5 (2021): 151-156. doi: https://doi.org/10.33588/rn.7205.2020292
Castro-Macías JI, Pérez-Reyes SP, García-Cazarez R, Pérez-Careta MC, Díaz-Campos MO, Salazar-Hörner DL, Preciado-Gutiérrez OU, Ruíz-Velázquez F. Tolerabilidad y efectos adversos del propofol en la prueba de Wada. [Tolerability and adverse effects of propofol in the Wada test]. Rev Neurol. 2021 Mar 01;72(5):151-156. doi: 10.33588/rn.7205.2020292. Spanish. PMID: 33616197.
Copy Download .nbib Format: NLM
Share it on

Rev Neurol. 2021 Mar 01;72(5):151-156. doi: 10.33588/rn.7205.2020292.

[Tolerability and adverse effects of propofol in the Wada test].

Revista de neurologia

[Article in Spanish]
J I Castro-Macías, S P Pérez-Reyes, R García-Cazarez, M C Pérez-Careta, M O Díaz-Campos, D L Salazar-Hörner, O U Preciado-Gutiérrez, F Ruíz-Velázquez

Affiliations

  1. Hospital Regional de Alta Especialidad del Bajío, León, México.
  2. Hospital Regional de Alta Especialidad del Bajío, León, España.

PMID: 33616197 DOI: 10.33588/rn.7205.2020292

Abstract

INTRODUCTION: The Wada test consists of the selective and reversible inhibition of a cerebral hemisphere by intracarotid injection of amobarbital in order to evaluate the laterality of language and memory. However, there are other anesthetic drugs such as propofol, as an alternative for the test.

OBJECTIVE: The objective of the study was to describe the tolerability and adverse effects (AE) of the use of propofol for the Wada test, during the presurgical study of patients with drug-resistant epilepsy.

METHODS: Consecutive patients with a diagnosis of drug-resistant structural epilepsy were selected who underwent the Wada test during the pre-surgical study in the period from June 2012 to May 2019. The patients were retrospectively evaluated. The AE were described according to the Mikuni classification, modified by Curot. The variables of sex, age, epileptic foci laterality, language laterality, lesional substrate, etiology and dose of administered Propofol were analyzed for any statistical significance.

RESULTS: A total of 74 patients, 40 men (54%), were studied. Forty-seven patients (63.5%) had at least one AE. The mean dose of propofol was 9.23 mg. The most frequent AE were tearing, sweating and red eye, corresponding to group I (57%). One patient developed convulsive status epilepticus, an important AE not previously described during the Wada test.

CONCLUSION: Performing the Wada test with propofol causes frequent mild adverse effects, which do not prevent its completion. We describe a case of convulsive status epilepticus as the only serious AE.

Publication Types